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A Human BRCA2 Complex Containing a
Structural DNA Binding Component
Influences Cell Cycle Progression
BRCA2 in transcriptional regulation (Milner et al., 1997).
However, most of the current data point to a role for the
BRCA2 protein in DNA repair. A number of laboratories
have reported that the BRCA2 protein interacts with
RAD51 (Mizuta et al., 1997; Wong et al., 1997; Chen et
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To decipher the role for the BRCA2 protein in cancerSummary
predisposition, attempts have been made to analyze the
induction of tumors in mice with a targeted deletionGermline mutations of the human BRCA2 gene confer
susceptibility to breast cancer. Although the function in BRCA2. However, contrary to expectation, mouse
strains heterozygous for mutations in BRCA2 failed toof the BRCA2 protein remains to be determined, mu-
rine cells homozygous for BRCA2 inactivation display show a predisposition to tumor formation (Connor et al.,
1997; Ludwig et al., 1997; Sharan et al., 1997; Suzuki etchromosomal aberrations. We have isolated a 2 MDa
BRCA2-containing complex and identified a structural al., 1997). Homozygosity caused early embryonic lethal-
ity at day 7.5–8.5 and was accompanied by retardedDNA binding component, designated as BRCA2-Asso-
ciated Factor 35 (BRAF35). BRAF35 contains a non- embryonic growth in vivo and in vitro (Ludwig et al.,
1997; Sharan et al., 1997; Suzuki et al., 1997). Interest-specific DNA binding HMG domain and a kinesin-like
coiled coil domain. Similar to BRCA2, BRAF35 mRNA ingly, embryonic survival was prolonged to day 10.5
when the analysis was performed with BRCA2 homozy-expression levels in mouse embryos are highest in
proliferating tissues with high mitotic index. Strik- gous mouse with a p53 null background (Ludwig et al.,
1997). Most recently, it was shown that some animalsingly, nuclear staining revealed a close association of
BRAF35/BRCA2 complex with condensed chromatin with a homozygous deletion of exon 11 survive to matu-
rity and succumb to thymic lymphomas (Friedman etcoincident with histone H3 phosphorylation. Impor-
tantly, antibody microinjection experiments suggest a al., 1998). Human BRCA2 exon 11 is composed of eight
internal repeats known as the BRC repeats that arerole for BRCA2/BRAF35 complex in modulation of cell
cycle progression. conserved in all mammalian BRCA2 proteins that have
been sequenced (Bork et al., 1996; Koonin et al., 1996).
To elucidate the molecular mechanism by whichIntroduction
BRCA2 induces its functional effects, we isolated the
predominant BRCA2-containing complex from HeLaMutations of one copy of the BRCA2 gene predisposes
humans to breast cancer (Wooster et al., 1995; Tavtigian cells and identified its components by mass spectrome-
try. Here we show that the BRCA2 complex containset al., 1996). Breast tumors from predisposed individuals
often display mutations in both alleles, suggesting that BRAF35 (BRCA2-associated factor 35), a structural DNA
binding protein with specificity for cruciform DNA. More-BRCA2 serves as a tumor suppressor (Collins et al.,
1995; Gudmundsson et al., 1995). In addition, deleteri- over, we provide evidence for association of the BRCA2/
BRAF35 complex with condensed chromatin during mi-ous alleles of BRCA1 and BRCA2 are responsible for
almost all familial ovarian cancer, and deleterious alleles tosis. Taken together, our studies suggest a role for
the BRCA2/BRAF35 complex in the timely progressionof BRCA2 are also involved in hereditary male breast
cancer (Easton et al., 1993; Miki et al., 1994; Wooster through mitosis.
et al., 1995; Tavtigian et al., 1996). BRCA2 encodes a
large protein of about 390 kDa that does not possess Results
any obvious homology with sequences available in the
public database (Tavtigian et al., 1996). Affinity-Purification
Recently, a report using in vitro transactivation assays of a BRCA2-Containing Complex
has suggested a role for the amino-terminal domain of To determine the polypeptide composition of BRCA2-
containing complex(es), HeLa nuclear or S100 (a side
fraction of nuclear extract preparation) extracts were§ To whom correspondence should be addressed (e-mail: shiekhattar@
wistar.upenn.edu). chromatographed sequentially to enrich for BRCA2-
Cell
248
Figure 1. Identification of BRAF35
(a) HeLa nuclear or S100 extract was fraction-
ated using phosphocellulose (P11) chroma-
tography. The 0.5 M KCl elution was concen-
trated on a DEAE-Sephacel column and
further fractionated by Superose 6 gel filtra-
tion or affinity chromatography using BRCA2
antibodies.
(b) The affinity-purified BRCA2 complex or
control eluate (protein A beads) was sepa-
rated in an SDS-polyacrylamide gel (4%–
15%), and proteins were visualized by silver
staining. Molecular masses of marker pro-
teins are indicated on the left and proteins
judged to be specific for the BRCA2 affinity
eluate are indicated by arrows.
(c) The primary amino acid sequence of
BRAF35. The conserved HMG domain is sin-
gle underlined and kinesin-like domain is
double underlined.
(d) Diagrammatic alignment of BRAF35
(AF331191), mouse BRAF (Smarce1-related,
Wattler et al., 1999; AAD15897), iBRAF
(AAF66706), D. melanogaster BRAF (AAF46682),
and C. elegans BRAF (T26108). The numbers
in the shaded boxes represent percent iden-
tity and similarity of each protein to human
BRAF35, respectively.
(e) Diagrammatic alignment of BRAF35 and
BAF57.
(f) Alignment of kinesin-like domains with cor-
responding sequences of related proteins.
Hydrophobic residues of the heptad repeats
of the kinesin-like domain are shaded.
containing complex(es) (Figure 1a). Analysis of these tained (Figure 1c). Blast analysis using BRAF35 as query
identified a second human open reading frame with exten-fractions by gel filtration chromatography revealed that
BRCA2 was a component of a 2 MDa complex (data not sive homology to BRAF35, designated iBRAF35 (imitation
BRAF35). This analysis also revealed Mus musculus Dro-shown). To purify this complex, DEAE-Sephacel frac-
tions were subjected to affinity-purification using mono- sophila melanogaster and Caenorhabditis elegans ho-
molog of BRAF35 (Figure 1d).and polyclonal anti-BRCA2 antibodies (Marmorstein et
al., 1998). Western blot analysis of the affinity-eluates Analysis of the predicted sequence of human BRAF35
indicated that it encodes a protein containing a singleconfirmed the presence of BRCA2 protein (data not
shown). However, the yields for the BRCA2 protein were sequence nonspecific HMG domain and a region with
two heptad repeats similar to the coiled-coil region ofvariable in different preparations, as it could not be effi-
ciently eluted from the affinity matrix. Polypeptides spe- kinesin. Interestingly, the only other protein with similar
structural domains to BRAF35 is BAF57, a subunit ofcifically eluted from the BRCA2 affinity matrix (Figure
1b) were analyzed by matrix-assisted laser desorption/ the human SWI/SNF complex (Wang et al., 1998). Both
proteins contain the nonspecific HMG box and the re-ionization time-of-flight mass spectrometry. This analy-
sis identified, among a number of proteins that were gion similar to the coiled-coil domain of kinesin (Figures
1e and 1f). It is noteworthy that both BRAF35 and BAF57specifically enriched by the BRCA2 antibodies, a 35
kDa species, designated BRAF35 (BRCA2-associated outside their HMG domains lack significant homology
to any ORFs in Sacchromyces cerevisiae.factor), as the predicted product of the R31109 cosmid
open reading frame.
BRAF35 Is Associated with a 2 MDa
BRCA2 ComplexBRAF35 Is an Evolutionary Conserved Protein
Based on the above information, expressed sequence To confirm the association of BRAF35 and BRCA2, we
employed several approaches. We purified the BRCA2tags containing the full-length BRAF35 protein were ob-
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Figure 2. BRAF35 Is a Component of the
BRCA2 Complex
(a) Purification Scheme. HeLa nuclear extract
was fractionated by chromatography as de-
scribed in Experimental Procedures. The
horizontal and diagonal lines indicate step-
wise and gradient elution, respectively. Con-
centrations are given in molars.
(b and c) Westrn blot analysis of the Hydroxy-
apatite and Superose 6 fractions (15 ml) using
anti-BRCA2 monoclonal antibodies (5.23) and
anti-BRAF35 antibodies (monoclonal mix).
(d, e, and f) Affinity eluate using C-terminal
polyclonal anti-BRCA2 (C20), N-terminal poly-
clonal anti-BRCA2 (N15), C-terminal poly-
clonal anti-BRAF35 antibodies, and control
polyclonal anti-cyclin H antibodies or control
IgG were separated in an SDS-polyacryl-
amide gel and proteins were immunoblotted
using anti-BRAF35 and anti-BRCA2 mono-
clonal antibodies. The numbers in the right
denote the molecular weight markers. 500 mg
of HeLa nuclear extract was used for the im-
munoprecipitations and HeLa NE denotes 50
mg of HeLa nuclear extract.
complex from HeLa nuclear extract using a conventional BRAF35 Is a Component of at Least Two
Complexes and Can Directly Interactchromatographic procedure following the scheme in
Figure 2a. BRAF35 coeluted with the BRCA2 protein with BRCA2
To determine the number of BRAF35-containing com-throughout the purification scheme (Figures 2b and 2c).
Analysis of the BRAF35/BRCA2 complex on the last plexes, we followed BRAF35 immunoreactivity following
the chromatographic scheme presented in Figure 3a.chromatograpic step revealed the precise coelution of
BRCA2 and BRAF35 as components of a large multipro- Analysis of Superose 6 gel filteration revealed two peaks
of immunoreactivity for BRAF35. A complex of approxi-tein (z2 MDa) complex (Figure 2c). We then used anti-
BRCA2 antibodies to specifically precipitate BRAF35 mately 2 MDa that contains BRCA2 eluted with a sharp
peak in fraction 18 and a second smaller BRAF35 com-from HeLa nuclear extract (Figure 2d). Based on the
known ability of these antibodies to enrich for BRCA2 plex (approximately 500 kDa) lacking BRCA2 (Figure
3a) eluting in fractions 26–30. Therefore, BRAF35 is a(around 5%–10% efficiency), we estimate that at least
2%–4% of endogenous BRAF35 was present in BRCA2 component of at least two complexes displaying differ-
ent molecular sizes.complex(es). Furthermore, the inability of the C-terminal
anti-BRCA2 antibodies to immunoprecipitate BRAF35 To determine whether BRAF35 can directly interact
with BRCA2, we performed protein–protein interactionfrom Capan-1 nuclear extract (containing a truncated
BRCA2 protein, Goggins et al., 1996) further attest to studies using GST-BRCA2 constructs spanning the
open reading frame (approximately 5 mg of each GST-the specific association of BRAF35 and BRCA2 (Figure
2e). CAPAN-1 cells harbor a truncation of BRCA2 construct was used, Figure 3b). This analysis revealed a
specific interaction of BRAF35 with a fragment of BRCA2(6174delT) on one allele, while the second allele is lost
(Goggins et al., 1996). Finally, anti-BRAF35 antibodies spanning the amino acids 1648–2190 contained within
BRC6 through 8 of BRCA2 (Figure 3b).specifically precipitate BRCA2 (Figure 2f). Taken to-
gether, these results demonstrate a specific associa- To address whether cancer-causing mutations in
BRCA2 disrupt the BRCA2/BRAF35 complex, we ana-tion of BRAF35 with a multiprotein BRCA2-containing
complex. lyzed the nuclear extract from CAPAN-1 cells by Su-
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were unable to reliably detect the truncated BRCA2 in
CAPAN-1 nuclear extract, consistent with the recent
report indicating that mutations in BRCA2 result in the
loss of nuclear localization signal (Spain et al., 1999).
These results are consistent with the disruption of 2 MDa
BRCA2/BRAF35 complex in CAPAN-1 nuclear extract.
BRAF35 Displays a Pattern of Expression Similar
to BRCA2
We next addressed the pattern of BRAF35 expression
in tissues. Western blot analysis using anti-BRAF35 anti-
bodies revealed the presence of BRAF35 in a wide vari-
ety of adult tissues examined with the highest levels
expressed in testis and ovary (data not shown). This is
consistent with the expression pattern of BRCA2 (Tav-
tigian et al., 1996). These results prompted us to analyze
the RNA expression pattern of BRAF35 in developing
mouse embryos using in situ hybridization. Marked re-
gional differences in mouse BRCA2 expression is first
seen at day E11.5 of embryonic development (Sharan
et al., 1997). Thus, we compared mouse BRAF35 expres-
sion at E11.5 to that of BRCA2. As shown in Figure 4,
BRAF35 displayed a nearly identical pattern of tissue
expression to that of BRCA2 with highest expression
observed in tissues with high mitotic index, such as the
proliferating ventricular zones of the fore-, mid-, and
hindbrain (Figures 4a–4d). These results are consistent
with the role for the BRAF35/BRCA2 complex in cells
during mitosis.
BRAF35 Decorates the Early Mitotic
Chromosomes during Initiation of Mitotic
Chromosome Condensation
To directly assess the role of BRAF35 in mitotic cells,
Figure 3. BRAF35 Is a Component of Two Complexes and Can Di- we examined mitotic HeLa cells using indirect immuno-
rectly Interact with BRCA2 fluorescence. Strikingly, anti-BRAF35 antibodies stain
(a) HeLa nuclear extract was fractionated by chromatography as mitotic chromosomes during early stages of chromo-
indicated. The horizontal and diagonal lines indicate stepwise and
some condensation (Figure 5). This staining is coinci-gradient elution, respectively, with KCl concentrations in molars.
dent with the phosphorylation of serine 28 (Ser-28) ofFractions from the final Superose 6 column were separated in an
SDS-polyacrylamide gel, and proteins were immunoblotted with histone H3, known to delineate condensed mitotic chro-
BRCA2 or BRAF35 antibodies. The void and a 670 kDa standard mosomes (Goto et al., 1999). Remarkably, at the onset
used for column calibration are shown below. of metaphase to anaphase transition, BRAF35 staining
(b) SDS-PAGE followed by Western blotting using anti-GST antibod-
is no longer visible while Ser-28 phosphorylation stillies of purified recombinant GST-BRCA2 fusion proteins synthesized
persists (Figure 5; early anaphase).as described in Experimental Procedures. Recombinant GST-
Since BRAF35 is a component of at least two com-BRCA2 fusion proteins (5 mg) denoted on the top of the figure were
incubated with bacterial lysate containing recombinant BRAF35 (10 plexes, one of which is lacking BRCA2, we analyzed
mg) as outlined in Experimental Procedures. Following elution with the mitotic chromosomes using both polyclonal and
glutathione, samples were subjected to Western blotting analysis monoclonal anti-BRAF35 and anti-BRCA2 antibodies
using anti-BRAF35 antibodies.
(Figure 6). To directly analyze the chromatin-associ-(c) SDS-PAGE followed by Western blot analysis of BRAF35. HeLa
ated structures, cells were stained following extractionor CAPAN-1 nuclear extract was fractionated using Superose 6
chromatography. The void and a 670 kDa standard used for column of the soluble material by detergent treatment (Nicker-
calibration are shown below. The numbers in the right denote the son et al., 1990). This staining was compared to staining
molecular weight markers. I denotes the input (15 ml of nuclear of condensed chromosomes using antibodies against
extract) for each column. While 15 ml was sufficient to detect
phosphorylated forms of Ser-10 (polyclonal) or Ser-28BRAF35 in Superose 6 fractions derived form HeLa nuclear extract,
(monoclonal) of histone H3. This analysis revealed thewe had to analyze 500 ml of CAPAN-1 derived fractions in order to
detect BRAF35. colocalization of BRAF35 and BRCA2 on mitotic chro-
mosomes coinciding with histone H3 phosphorylation
(Figures 6a–6d). Taken together, these results suggestperose 6 gel filtration. In contrast to the 2 MDa BRAF35
a role for the BRAF35/BRCA2 complex in early phasescomplex in HeLa cells, CAPAN-1 cells contained a much
smaller complex at 670 kDa (Figure 3c). Moreover, we of mitotic cell cycle progression.
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Figure 4. BRAF35 and BRCA2 Have Overlap-
ping Expression Patterns during Develop-
ment in Tissues with High Mitotic Index
In situ hybridization of sagittal sections from
E11.5 mouse embryos reveals expression of
both BRAF35 (a and c) and BRCA2 (b and d)
in strikingly similar patterns. mRNA expres-
sion is detected by radioactive in situ hybrid-
ization and appears white. Cell nuclei are
counterstained with Hoeschst 33258 nuclear
dye (red). Both genes are expressed in the
neuroepithelium of the neural tube (ne) and
in the first and second branchial arches (ba),
as well as in the ventricular zone of the neu-
roepithelium within the midbrain (mb) and
hindbrain (hb) adjacent to the third ventricles
(V3) and fourth ventricles (V4), respectively.
ht 5 heart, drg 5 dorsal root ganglia.
BRAF35 Displays Specific Binding either affinity-purified anti-BRAF35 or anti-BRCA2 anti-
bodies and injected cells were analyzed 12 or 14 hrto Cruciform DNA
The condensin complex involved in chromosome con- following release from the block (Figure 8a). Cells were
stained to identify the injected antibodies and counter-densation was shown to display high affinity for struc-
tured DNA, such as cruciform DNA (Kimura and Hirano, stained with anti-human CENP-F antibodies (Liao et al.,
1995). CENP-F is a reliable marker for identifying cells1997). The localization of BRAF35 to condensed chro-
matin and the fact that a unique feature of HMG domain in G2 because it is only detected after cells have com-
pleted S phase. S phase cells that incorporate BrdUallows high affinity for DNA with sharp bends, such as
four-way junction (4WJ) DNA (Bianchi et al., 1989), are CENP-F negative while cells that have completed S
phase and do not incorporate BrdU are CENP-F positiveprompted us to examine the DNA binding activity of
BRAF35 (Figure 7a). We compared the DNA binding ac- (T. Yen personal communication). Mitotic and newly di-
vided cells (telophase/early G1) were visually identifiedtivity of BRAF35 to that of the BAF57 HMG domain
(Wang et al., 1998) (Figure 7b). and counted. Following release from the block, the IgG
injected cells entered mitosis after approximately 10 hrSimilar to that of BAF57, recombinant BRAF35 dis-
played strong binding to 4WJ DNA in gel-shift assays and exited after 12 hr (Figure 8b). In contrast to IgG
injected cells, injection of anti-BRCA2 or anti-BRAF35(Figure 7c). However, in contrast to two other sequence-
specific HMG domain-containing proteins, LEF1 and antibodies results in a pronounced delay in entry into
mitosis as evident by a 3-fold increase in CENP-F (G2)-mTF1, BRAF35 did not display detectable DNA binding
activity when either of the duplex “arms” of the 4WJ positive cells 12 hr after release from the thymidine block
DNA were used as probes (Figure 7d, and data not (Figures 8b and 8c). Analysis of anti-BRCA2 or anti-
shown). These results demonstrate that the DNA binding BRAF35 injected cells at 14 hr after release indicated
properties of BRAF35 are highly specific and similar that more of the injected cells were able to enter mitosis,
to that of the condensin complex (Kimura and Hirano, although a significant number were still delayed in G2
1997). (Figure 8b). Importantly, analysis of cells injected with
antibodies against various proteins that are important
for mitotic cell cycle progression including CENP-E,Microinjection of Anti-BRCA2 or Anti-BRAF35
hBUBR1, hZW10, hROD, and CENP-F failed to displayAntibodies into Synchronized HeLa Cells
a delay in entry into mitosis attesting to the specificityCauses a G2 Cell Cycle Delay
of anti-BRCA2 and anti-BRAF35 antibodies (data notTo functionally assess the role of the BRCA2/BRAF35
shown).complex in cell cycle progression, synchronized HeLa
cell nuclei (double thymidine block) were injected with Interestingly, following injection with anti-BRAF35,
Cell
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Figure 5. BRAF35 Delineates Condensed
Chromosomes during Prophase to Meta-
phase Transition
Hela cells were stained using anti-BRAF35
polyclonal antibodies raised against the first
twenty amino acids of BRAF35 (a-BRAF35
poly (N)) according to the protocol outlined in
Experimental Procedures. Mitotic cells were
counterstained with the antibody against
the histone H3 phosphorylated at serine 28
(a-P-H3 (S28)).
anti-BRCA2, or anti-IgG antibodies, analysis of G2 cells for the subsequent segregation of chromosomes in ana-
phase and is essential for maintaining the integrity ofusing anti-phosphorylated histone H3 antibodies (identi-
fies cells in initial phases of chromatin condensation) genetic information throughout mitosis. Recent genetic
and biochemical studies in eukaryotes have pointed torevealed a similar percentage of cells (approximately
5%) displaying phosphorylation of Ser-28 of histone H3. two distinct complexes, condensin and cohesin, as play-
ing a central role in chromosome condensation and sis-These results indicate that the impediment in entry into
mitosis by microinjection of anti-BRCA2 and anti- ter-chromatid cohesion, respectively (Hirano, 1999). The
emerging theme from these studies is that such regula-BRAF35 antibodies is likely due to events that occur
following Ser-28 phosphorylation. Taken together, these tory complexes are not only involved in chromosome
results suggest a role for BRCA2/BRAF35 complex in segregation but also play a fundamental role in DNA
the timely progression through mitosis. repair and dosage compensation (Chuang et al., 1994;
Hirano, 1999). Similar to such regulatory complexes, the
BRAF35/BRCA2 complex not only confers a regulatoryDiscussion
role in progression through mitosis but also has been
reported to be involved in DNA repair (Mizuta et al.,The novelty of this work lies in the following. First, it
1997; Wong et al., 1997; Chen et al., 1998; Marmorsteindemonstrates the presence of BRCA2 in a 2 MDa multi-
et al., 1998), consistent with a dual role for this complexprotein complex. Second, through characterization of
in modulation of DNA repair and cell cycle regulation.BRAF35, a DNA binding component of the complex has
It is also conceivable that the BRAC2/BRAF35 com-been identified. Third, it establishes BRAF35 as an archi-
plex modulates the components of the chromosometectural DNA binding protein capable of binding to cruci-
condensation/segregation machinery once recruited toform DNA. Fourth, it reveals an intimate association of
the mitotic chromosome. Indeed, the fact that at theBRA35 and BRCA2 with chromatin during early phases
onset of metaphase to anaphase transition, the BRAF35/of mitotic chromosome condensation. Finally, through
BRCA2 complex can no longer be detected at the mitoticantibody microinjection experiments, it suggests a role
chromosomes suggests a role for the complex in thefor the complex in regulation of cell cycle progression.
early phases of chromosome condensation. Further-Chromosome condensation is a cellular process in
more, the spontaneous accumulation of chromosomalwhich entangled chromatin fibers are resolved and
abnormalities, including breaks and aberrant chromatidpackaged into physically separate compact structures,
the mitotic chromosomes. This process is prerequisite exchanges, observed in cells from BRCA2-deficient
BRAF35/BRCA2 Complex Has a Role in Cell Cycle
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Figure 6. BRAF35 and BRCA2 Are Localized
to Condensed Chromosomes
(a and b) HeLa cells were stained with mono-
clonal and polyclonal anti-BRCA2 and anti-
BRAF35 antibodies following the protocol
outlined in Experimental Procedures. Mitotic
cells were counterstained with either mono-
clonal antibodies against phosphorylated
form of Ser-28 of histone H3 or polyclonal
antibodies against the phosphorylated form
of Ser-10 of histone H3.
(c and d) Mitotic chromosomes were stained
with monoclonal and polyclonal anti-BRAF35
or anti-BRCA2. Merge denotes the overlay of
green and red signals resulting in the appear-
ance of yellow.
0.1 mM EDTA, 5 mM BME, 0.2 mM PMSF, 0.1% NP-40), then themouse (Yu et al., 2000) are reminiscent of a role for the
support was washed successively with NEBB buffer containing 500complex in chromosome segregation.
mM NaCl, 0.1% NP-40; 500 mM NaCl, 0.5% NP-40; 1.0 M NaCl,The identification of BRAF35 as a structural DNA bind-
0.1% NP-40; and 20 mM NaCl, 1.0% NP-40. The washed beads
ing component of the BRCA2 complex also suggests a were then eluted with three column volumes of 100 mM glycine,
role for this complex in association with sites of unusual pH 3.0.
DNA architectures such as the ones formed during DNA
recombinational repair. Such recombinational events Conventional Chromatographic Purification
are frequently required during the cell cycle progression of the BRCA2 Complex
The BRCA2 complex was purified from 2 g of HeLa nuclear extract(Aguilera et al., 2000). Our results also extend the pro-
(Figure 2a). Nuclear extract was loaded on a 250 ml column ofposed role for BRCA2 in DNA repair and recombination
phosphocellulose (P11, Whatman) and fractionated stepwise by theby identifying BRAF35 as a component of the complex
indicated KCl concentrations in buffer A (20 mM Tris.HCl, pH 7.9,
that might serve to target it to sites of DNA damage. It 0.2 mM EDTA, 10 mM bME, 10% glycerol, 0.2 mM PMSF). The P11
is noteworthy that the human BRAF35 gene maps to 0.5 M KCl fraction (250 mg) was loaded on a 45 ml DEAE-Sephacel
chromosome sub-band 19p13.3. As loss of heterozy- column (Pharmacia) and eluted with 0.35 M KCl. The 0.35 M KCl
elution (140 mg) was dialyzed to 700 mM NH4SO4 in buffer HB (20gosity at 19p13.3 has been reported in about 50% of
mM Hepes, pH 7.6, 4 mM dithiothreitol, 0.5 mM EDTA, 10% glycerol,ovarian cancers (Jenkins et al., 1993; Wang et al., 1999),
0.5 mM PMSF, 1 mg/ml aprotinin, 1 mg/ml leupeptin, and 1 mg/mlBRAF35 constitutes a candidate tumor suppressor gene
pepstatin) and loaded on a Butyl Superose (Pharmacia). The column
in such cancers. was resolved using a linear 10 column volume gradient of 700 to 0
mM NH4SO4 in buffer HB. BRCA2-containing fractions were dialyzed
to 10 mM KxPO4 in buffer HA (5 mM Hepes, pH 7.6, 1 mM dithiothrei-Experimental Procedures
tol, 0.5 mM PMSF, 10 mM CaCl2, 10% glycerol, 40 mM KCl, 1 mg/
ml aprotinin, 1 mg/ml leupeptin, and 1 mg/ml pepstatin) and loadedAffinity Purification of BRCA2 from Nuclear or S100 Extract
Affinity purification of BRCA2-associated polypeptides was per- on a BioScale CHT5-I column (BioRad). The column was resolved
using a linear 15 column volume gradient of 10 to 600 mM KxPO4formed using either mono- or polyclonal anti-BRCA2 antibodies
(Marmorstein et al., 1998). Antibodies were coupled to 1 ml protein in buffer HA. Fractions containing BRCA2 were dialyzed to 100
mM KCl in buffer A containing 1 mg/ml aprotinin, leupeptin, andA agarose beads (Repligen) as described (Harlow and Lane, 1988).
The resin was incubated overnight at 48C with 10 mg HeLa DEAE- pepstatin, and loaded on Heparine-5PW (TosoHaas). The column
was resolved using a linear 20 column volume gradient of 100 toSephacel precleared with 1 ml protein A beads. Binding was carried
out in NEBB buffer (250 mM NaCl, 30 mM Tris 7.6, 10% glycerol, 450 mM KCl in buffer A containing 1 mg/ml aprotinin, leupeptin, and
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Figure 7. BRAF35 Can Specifically Bind to Cruciform DNA
(a) Diagram of the structure of the 4WJ DNA and the two duplex DNA that correspond to its “arms.”
(b) The full-length BRAF35 and truncated BAF57 proteins were purified from E. coli and analyzed on a Coomassie blue-stained SDS-gel (10%).
(c) The DNA binding activities of BRAF35 and truncated BAF57 were analyzed by gel mobility assays using 4WJ DNA as the probe. The protein
concentrations were 0.1, 0.3, 1.0, and 1.5 mg, respectively.
(d) The DNA binding activity of BRAF35 was compared to that of LEF1 and mTF1 proteins using the duplex “arms” of 4WJ DNA as probes.
The protein concentration was 0.3 and 1.0 mg for BRAF35 and 1.0 mg for LEF1 and mTF1.
pepstatin. Fractions containing BRCA2 were dialyzed to 100 mM embedded embryos after fixation in 4% paraformaldehyde and de-
hydration. Slides were coated with photographic emulsion, exposedKCl in buffer A containing 1 mg/ml aprotinin, leupeptin, and pep-
statin, and loaded on DEAE-5PW (TosoHaas). The column was re- for 5–10 days, counterstained with Hoechst 33258 nuclear dye and
photographed using darkfield and fluorescent illumination. Figuressolved using a linear 15 column volume gradient of 100 to 500
mM KCl in buffer A containing 1 mg/ml aprotinin, leupeptin, and were processed using Adobe Photoshop software.
pepstatin. BRCA2-containing fractions were fractionated on a Su-
perose 6 HR 10/30 (Pharmacia) equilibrated in 0.7 M KCl in buffer Immunoprecipitation and Immunofluorescence
A containing 0.1% NP-40, and 1 mg/ml aprotinin, leupeptin, and Immunoprecipitation experiments were performed as described
pepstatin. (Bochar et al., 2000a, 2000b). Briefly, HeLa or Capan-1 nuclear ex-
For analysis of multiple complexes, BRCA2 was purified from 1.2 tract (500 mg) was incubated with different antibodies (2–5 mg) bound
g of HeLa nuclear extract as illustrated in Figure 3a. Nuclear extract to protein A beads (10 ml of packed beads, Repligen). The beads were
was loaded on a 200 ml column of phosphocellulose (P11, Whatman) then washed three times with a buffer containing 20 mM Tris-HCl,
and fractionated stepwise by the indicated KCl concentrations in pH 7.5, 100 mM NaCl, 0.05% NP-40. Following centrifugation, beads
buffer A (20 mM Tris.HCl, pH 7.9, 0.2 mM EDTA, 10 mM bME, 10% were resuspended in 20 ml of protein sample buffer and boiled for
glycerol, 0.2 mM PMSF). The P11 0.5 M KCl fraction (200 mg) was 5 min. Eluates were separated by SDS-PAGE and transferred onto
loaded on a 20 ml DEAE-Sephacel column (Pharmacia) and eluted a polycvinylidence difluoride membrane (Millipore) for Western
with 0.35 M KCl. A portion of the 0.35 M KCl elution (10 mg) was blotting.
dialyzed to 100 mM KCl in buffer A and loaded on a MonoS 5/5 Immunofluorescence experiments were performed using mono-
column (Pharmacia). The column was resolved using a linear 10 clonal and polyclonal antibodies against BRCA2 and BRAF35 as
column volume gradient of 100 to 650 mM KCl. Fractions containing described (Yarden and Brody, 1999). For experiments shown in
BRCA2 (500 mM KCl, 0.5 mg) were dialyzed to 700 mM KCl, 0.1% Figure 6, cells grown on coverslips were washed with ice-cold PBS
NP-40 in buffer A and loaded on a Superose 6 HR 10/30 (Pharmacia) twice, then treated with ice-cold cytoskeleton buffer containing: 10
equilibrated in the same buffer containing 1 mg/ml aprotinin, leupep- mM PIPES pH 6.8, 100 mM NaCl, 300 mM sucrose, 3 mM MgCl2, 1
tin, and pepstatin. mM EGTA, 0.5% triton X-100. After 5 min on ice, cells were aspirated
and were treated with ice-cold stripping buffer containing: 10 mM
Gel-Shift Assays Tris-HCl pH 7.4, 10 mM NaCl, 3 mM MgCl2, 1% Tween 40 (v/v), 0.5%
The 4WJ DNA and its duplex DNA “arms” were prepared according sodium deoxycholate (v/v) for 5 min. Cells were then washed three
to Bianchi (Bianchi et al., 1989). Binding reactions were performed times with ice-cold PBS and fixed in modified Streck tissue fixative
as described (West and Austin, 1999). Full-length BRAF35 was pre- (150 mM 2-bromo-2-nitro-1,3-propanediol (Sigma), 108 mM diazo-
pared similar to that described for BAF57 (Wang et al., 1998). lidinyl urea (Sigma), 10 mM Na Citrate, 50 mM EDTA pH 5.7) for 30
min at room temperature. Following fixation, cells are washed in
PBS and permeabilized for 15 min using 100 mM Tris-HCl pH 7.4,In Situ Hybridization
Radioactive in situ hybridization was performed as described (Lutz 50 mM EDTA and 0.5% Triton X-100. Cells are then blocked using
10% FCS in PBS and 0.1% azide and incubated with the primaryet al., 1994) using antisense probes prepared from EST AA007769
(BRAF35) and AA571559 (BRCA2) and 8 mM sections of paraffin- and secondary antibodies
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Figure 8. Microinjection of Antibodies against
BRAF35 or BRCA2 into Synchronized HeLa
Cells Delays Entry into Mitosis
(a) Diagram of microinjection experiments.
HeLa cells were synchronized by double thy-
midine block and released. Anti-BRAF35,
anti-BRCA2, or preimmune IgG was injected
into the nuclei at S phase, and cells were
allowed to proceed through mitosis.
(b) The percent of cells in different stages of
the cell cycle following microinjection of anti-
BRAF35, anti-BRCA2, or preimmune anti-
IgG. The cells were analyzed at 12 and 14
hr following release. Approximately 450 cells
were microinjected in four independent ex-
periments.
(c) A typical microinjected cell displaying
G2 delay following microinjection of anti-
BRAF35 antibody. Each cell was also stained
for DAPI, BRCA2, and CENP-F.
Monoclonal anti-BRCA2 antibodies (4.56 and 5.23) were raised with 150 mM NaCl, 500 mM NaCl, and 150 mM NaCl in Buffer G.
Approximately 10 mg of overexpressed E.coli BRAF35 (pET-28b,against a BRCA2 fusion protein encoding amino acids 2959–3418.
We also developed monoclonal antibodies (4.21) to a BRAF35 fusion Novagen) lysate was added and beads were incubated for 3 hr at
48C. Beads were washed two times each with 300 mM NaCl, andprotein (amino acids 103–317) using The Wistar Institute Hybridoma
Facility. Polyclonal antibodies were also developed against the last 150 mM NaCl in Buffer G, and eluted with 30 mM glutathione plus
150 mM NaCl in Buffer G. Samples were subjected to SDS-PAGEtwenty amino acids of BRCA2 (C20) and BRAF35 and the first twenty
amino acid of BRAF35 (Poly (N)). All polyclonal antibodies were followed by Western blotting to determine the presence of BRAF35.
affinity purified using the appropriate peptides. Antibodies against
phosphorylated S10 and S28 were purchased through UBI and Antibody Microinjection Experiments
Hela cells plated on No. 1 coverslips were synchronized by a doubleSigma, respectively.
thymidine block. Rabbit anti-BRCA2, BRAF35, and nonimmune anti-
bodies were concentrated to z5 mg/ml in PBS and injected intoGST-BRCA2 Fusion Proteins and GST
Pull-Down Experiments nuclei of cells 30 to 60 min following release form the block using an
Eppendorf semi-automated microinjector and manipulator mountedGST-BRCA2 fusion protein constructs were a gift from F. J. Couch.
GST-BRCA2 fusion proteins #1 to #7 correspond to amino acids on a Nikon TE300 inverted microscope. Samples were taken at
approximately 12 to 14 hr after release from the G1/S boundary195–784, 705–1217, 1171–1658, 1648–2190, 2114–2608, 2634–2999,
and 2959–3418, respectively. GST and GST-BRCA2 (pGEX, Amer- when neighboring uninjected cells or cells injected with nonimmune
IgG had mostly exited mitosis. Cells were fixed in 3.7% paraformal-sham Pharmacia) fusion proteins were expressed in E. coli BL21.
Cells were harvested and lysed by sonicating in 150 mM NaCl in dehyde/PBS for 8 min, permeabilized in 0.2% Triton X-100/PBS/
0.1% BSA for 5 min, washed in PBS/0.1% BSA, and stained. InjectedBuffer G (50 mM Tris, pH 8.0, 10% glycerol, 0.5% Triton X-100, 0.5
mM PMSF, 1 mg/ml aprotinin, 1 mg/ml leupeptin, and 1 mg/ml pep- antibodies were detected with FITC anti-rabbit secondary antibod-
ies (Jackson Immunoresearch). Cells were also costained with VDstatin). The cell lysates were cleared by centrifugation (105,000 3
g for 60 min at 48C). Concentration of GST or GST-BRCA2 fusion human autoimmune serum to detect CENP-F (Rattner et al., 1993),
rat anti-phospho Ser-10 H3, and visualized with Cy5 conjugatedproteins in cell lysates was determined by estimation of protein
concentration by Coomassie staining of SDS-PAGE samples puri- anti-human (Jackson Immunoresearch) and Alexa594 conjugated
anti-rat secondary antibodies (Molecular Probes), respectively. Cov-fied by affinity chromatography on glutathione-Sepharose (Amer-
sham Pharmacia). Cell lysates containing approximately 5 mg of erslips were visualized with a Nikon Microphot upright microscope
with a 1003 objective and images were captured with an 8 bit CCDGST-BRCA2 fusion protein were mixed with 10 ml glutathione-Seph-
arose, incubated for 3 hr at 48C, and washed three times each camera driven by Signal Analytics image processing program.
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